Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "Medivation, Inc." (MDVN) Report Updated: Nov 23, 2015 | Print This Page

Get more stock ratings by Louis Navellier

"Medivation, Inc." (MDVN)

Rating: Sell Volatility: Conservative
Total Grade: D Industry: Biotechnology
Competitors: REGN, DYAX, EXEL, CNCE

Stock Analysis

Rating: Monthly View

November December January February March April May June July August September October

Rating: Weekly View

This Week: D down downgrade
Last Week: C same upgrade
Two Weeks Ago: D up downgrade
service keys

"Medivation, Inc."© quotemedia

Company Profile

Medivation, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for the treatment of serious diseases in the United States and Europe. The company’s lead development candidate includes MDV3100, a molecule, which is in Phase-III development for the treatment of castration-resistant prostate cancer. Medivation, Inc. has collaboration with Astellas for the development, manufacture, and commercialization of MDV3100 for the treatment of prostate cancer. The company was founded in 2003 and is headquartered in San Francisco, California.

Recent News: "Medivation, Inc."